How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/autologous-hematopoietic-stem-cell-transplantation-for-ewing-s-sarcoma-family-of-tumors.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Busulfex	busulfan	Waylis	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1954-01-01
busulfex	busulfex	Dana-Farber Cancer Institute		Matrix metalloproteinase-9
Busilvex	Busilvex	medac GmbH		Matrix metalloproteinase-9
Busulphan	Busulphan	University of Birmingham		Matrix metalloproteinase-9

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Dana-Farber Cancer Institute · 1 drug in Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors
University of Birmingham · 1 drug in Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors
Waylis · 1 drug in Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors
medac GmbH · 1 drug in Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors:

Cite this brief

Drug Landscape (2026). Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/autologous-hematopoietic-stem-cell-transplantation-for-ewing-s-sarcoma-family-of-tumors. Accessed 2026-06-10.

Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing